Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Browse by Series:

Discerning HIPEC

Insights from: Wells A. Messersmith, MD, FACP, University of Colorado Cancer Center
Published: Wednesday, Jun 20, 2018



Transcript: 

Wells A. Messersmith, MD, FACP: The European HIPEC study was a very high-impact trial that was presented at ASCO 2018, and we await full details of the study. The take-home message was that chemotherapy in a cytoreductive procedure didn’t really seem to add benefit to just surgery alone. HIPEC is a fairly controversial area, and there’s a lot of geographical variation in terms of what heated intraperitoneal chemotherapy even means, what the contribution of temperature is, how high the temperature should be, what exactly the chemotherapy agents should be, and what its role is in terms of what it’s really adding to this surgery. What this trial has indicated is that the chemotherapy does not add much at all to the surgery.

And so, it will be interesting to see how centers that use HIPEC—and it tends to be done in fairly specialized centers—react to this data. I would commend the Europeans on getting this done, because trials in the United States studying HIPEC don’t tend to accrue well. We have not been able to successfully carry out these trials, because people have either tended to believe in it or not. I look forward to further data coming out of that trial in terms of who might benefit from including chemotherapy regarding those surgical patients.

Transcript Edited for Clarity 
SELECTED
LANGUAGE
Slider Left
Slider Right


Transcript: 

Wells A. Messersmith, MD, FACP: The European HIPEC study was a very high-impact trial that was presented at ASCO 2018, and we await full details of the study. The take-home message was that chemotherapy in a cytoreductive procedure didn’t really seem to add benefit to just surgery alone. HIPEC is a fairly controversial area, and there’s a lot of geographical variation in terms of what heated intraperitoneal chemotherapy even means, what the contribution of temperature is, how high the temperature should be, what exactly the chemotherapy agents should be, and what its role is in terms of what it’s really adding to this surgery. What this trial has indicated is that the chemotherapy does not add much at all to the surgery.

And so, it will be interesting to see how centers that use HIPEC—and it tends to be done in fairly specialized centers—react to this data. I would commend the Europeans on getting this done, because trials in the United States studying HIPEC don’t tend to accrue well. We have not been able to successfully carry out these trials, because people have either tended to believe in it or not. I look forward to further data coming out of that trial in terms of who might benefit from including chemotherapy regarding those surgical patients.

Transcript Edited for Clarity 
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x